Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™ GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, [….]
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
Covid 19 Timeline Year 2020 *click article titles below to read original BioBuzz content from the past year MARCH 4/7/2020 Coronavirus Pandemic Good News Roundup Sheds Light Amidst Trying COVID-19 [….]
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.
Novavax is Building a Global Tech Transfer Team to Rapidly Deliver 2 Billion COVID-19 Vaccine Doses Around the World
Gaithersburg, Maryland’s Novavax has skyrocketed to national and global prominence during the coronavirus pandemic. In an incredibly short time, the company has advanced its SARS-CoV-2 vaccine candidate into Phase III trials and received FDA fast track designation, putting its vaccine very close to potential FDA approval.
This year, more than ever before, we’ve seen just how important it is for us all to stay connected and work together to build a stronger biotech ecosystem. In the face of great adversity, the biotech community has risen to the challenge and formed new collaborations and partnerships to innovate and rapidly develop new medicines and tools to help us beat this pandemic.
Over the past nine months, more than $7 billion in federal funding has poured into the BioHealth Capital Region aimed at the battle against COVID-19 and has shown a spotlight on the broad impact biopharma life science companies and academic institutions are making in the fight against the pandemic.
Entry Level to Senior Leader in Biotech: Career Women Becoming Fearless Podcast Series Showcases Stories of Career Women Becoming Fearless. Are you looking to move into a leadership position? If [….]
Over the past nine months, more than $7 billion in federal money has poured into the BioHealth Capital Region in support of therapies, diagnostics, and vaccines against COVID-19. In that short time, the region has shown its importance in halting the spread of the ongoing pandemic.